Middle East & Africa Enzyme Replacement Therapy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Enzyme Type (Alglucosidase Alfa, Agalsidase Beta, Imiglucerase, Idursulfase, Galsulfase, Velaglucerase Alfa, and Other Enzymes), Therapeutic Conditions (Gaucher's Disease, Fabry's Disease, MPS, Pompe's Disease, SCID, and Other Therapeutic Conditions), Route of Administration (Parenteral and Oral), and End User (Hospitals, Infusion Centers, and Others)
The enzyme replacement therapy market in the Middle East & Africa is expected to grow from US$ 297.32 million in 2022 to US$ 386.56 million by 2028; it is estimated to grow at a CAGR of 4.5% from 2022 to 2028.
Rising Prevalence of Lysosomal Storage Diseases (LSDs)
The leading cause of lysosomal storage diseases (LSDs) is mutations in the genes responsible for encoding a lysosomal enzyme. LSDs are characterized as an inborn metabolism error that results in an enzyme's absence or deficiency. Infants and children suffer are prone to LSDs as children can inherit the defective gene from one or both parents. However, since the last decade, the pattern has been changing, and LSDs are more common in adults. LSDs can lead to approximately 70 ailments, including Gaucher disease, Niemann-Pick disease, Fabry disease, Tay-Sachs disease, Mucopolysaccharidoses (MPS) diseases, and Pompe disease. These disorders are individually rare, but collectively they are significantly prevalent and affect 1 in 5,000 live births. There are limited treatments for many of LSDs. However, progress is being made in terms of therapies and treatments available for a few LSDs, thereby significantly improving the quality of life for those affected. For instance, enzyme replacement therapy has proven effective for individuals with Gaucher disease type I, II, and III. Enzyme replacement therapy helps improve anemia symptoms, low platelet counts, and skeletal issues and helps reduce liver and spleen enlargement. Thus, the rising prevalence of LSDs and limited therapies to cure the disease are driving the growth of the enzyme replacement therapy market in the Middle East & Africa.
Market Overview
The Middle East & Africa enzyme replacement therapy market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia was this region's largest enzyme replacement therapy market in 2021. According to an article published in the Journal of Applied Hematology in 2020, the prevalence is higher than currently reported in the available literature. This might be mainly due to the high percentage of consanguinity, especially among tribes. Gaucher disease is underdiagnosed in Saudi Arabia. It is sometimes misdiagnosed with other hematological disorders. Additionally, according to the same study mentioned above, in Saudi Arabia, around 75 patients have been diagnosed with Gaucher disease; however, there is a huge under-diagnosis or misdiagnosis gap for Gaucher disease. The incidence is expected to be much higher due to high consanguinity and a high pregnancy rate per family. Enzyme replacement therapy (ERT) is an effective treatment of Gaucher disease. A body of evidence from the Gaucher registry, sponsored by the International Collaborative Gaucher Group (ICGG), indicates that enzyme replacement therapy reverses both visceral and hematological manifestations of Gaucher disease and relieves skeletal symptoms, leading to a better quality of life. Further, the Government of Saudi Arabia launched the Saudi Vision 2030 program to reduce oil dependence and diversify other sectors, including healthcare, which is leading to the significant development in healthcare services and the high adoption rate of advanced technologies. Under the vision, universities from Saudi Arabia have contributed 93% of the national scientific research output, boosting the Ministry of Education's efforts to promote the research and innovation system. Moreover, pharmaceutical R&D and clinical trials play an essential role in improving healthcare, directly benefiting patients, and making the latest and greatest pharmaceutical industry advancements available and accessible to a broader pool of patients in Saudi Arabia. Thus, above discussed factors are boosting the growth of the enzyme replacement therapy market in Saudi Arabia.
Middle East & Africa Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US$ Million)
Middle East & Africa Enzyme Replacement Therapy Market Segmentation
The Middle East & Africa enzyme replacement therapy market is segmented into enzyme type, therapeutic conditions, route of administration, end user, and country.
- Based on enzyme type, the market is segmented into alglucosidase alfa, agalsidase beta, imiglucerase, idursulfase, galsulfase, velaglucerase alfa, and other enzymes. The other enzymes segment registered the largest market share in 2022.
- By therapeutic conditions, the market is segmented into Gaucher's disease, Fabry's disease, MPS, Pompe's disease, SCID, and other therapeutic conditions. The Gaucher's disease segment held the largest market share in 2022.
- In terms of route of administration, the market is bifurcated into parenteral and oral. The parenteral segment held a larger market share in 2022.
- From end user point of reference, the market is segmented into hospitals, infusion centers, and others. The hospitals segment held the largest market share in 2022.
- Based on country, the market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the market in 2022.
Sanofi; BioMarine Pharmaceutical Inc; Takeda Pharmaceutical Company Limited; AbbVie Inc; Janssen Pharmaceutical (Johnson & Johnson Services, Inc.); Alexion Pharmaceutical, Inc. (AstaZeneca); Amicus Therapeutics; Recordati S.p.A; Recordati S.p.A; CHIESI farmaceutici S.p.A; and Pfizer Inc are among the leading companies operating in the enzyme replacement therapy market in the region.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 MEA Enzyme Replacement Therapy Market – By Enzyme Type
1.3.2 MEA Enzyme Replacement Therapy Market – By Therapeutic Conditions
1.3.3 MEA Enzyme Replacement Therapy Market – By Route of Administration
1.3.4 MEA Enzyme Replacement Therapy Market – By End User
1.3.5 MEA Enzyme Replacement Therapy Market – By Country
2. MEA Enzyme Replacement Therapy Market– Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Enzyme Replacement Therapy Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Middle East & Africa – PEST Analysis
4.3 Expert Opinion
5. MEA Enzyme Replacement Therapy Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Lysosomal Storage Diseases (LSDs)
5.1.2 Rapid Regulatory Approval with Other Benefits for Drug with Orphan Drug Designation
5.2 Market Restraints
5.2.1 Cutthroat Competition among Market Players
5.3 Market Opportunities
5.3.1 Increasing Partnerships and Collaborations to Synergize the Business
5.4 Future Trends
5.4.1 Innovative Developments in ERT
5.5 Impact Analysis
6. Enzyme Replacement Therapy Market– MEA Analysis
6.1 MEA Enzyme Replacement Therapy Market Revenue Forecast and Analysis
7. MEA Enzyme Replacement Therapy Market Revenue and Forecasts To 2028– by Enzyme Type
7.1 Overview
7.2 MEA Enzyme Replacement Therapy Market, By Enzyme Type 2021 & 2028 (%)
7.3 Alglucosidase Alfa
7.3.1 Overview
7.3.2 Alglucosidase Alfa Revenue and Forecast to 2028 (US$ Million)
7.4 Agalsidase Beta
7.4.1 Overview
7.4.2 Agalsidase Beta - Revenue and Forecast to 2028 (US$ Million)
7.5 Imiglucerase
7.5.1 Overview
7.5.2 Imigluceras - Revenue and Forecast to 2028 (US$ Million)
7.6 Idursulfase
7.6.1 Overview
7.6.2 Idursulfase - Revenue and Forecast to 2028 (US$ Million)
7.7 Galsulfase
7.7.1 Overview
7.7.2 Galsulfase - Revenue and Forecast to 2028 (US$ Million)
7.8 Velaglucerase Alfa
7.8.1 Overview
7.8.2 Velaglucerase Alfa - Revenue and Forecast to 2028 (US$ Million)
7.9 Other Enzymes
7.9.1 Overview
7.9.2 Other Enzymes - Revenue and Forecast to 2028 (US$ Million)
8. MEA Enzyme Replacement Therapy Market Analysis and Forecasts To 2028 – By Therapeutic Conditions
8.1 Overview
8.2 MEA Enzyme Replacement Therapy Market, By Therapeutic Conditions 2021 & 2028 (%)
8.3 Gaucher's Disease
8.3.1 Overview
8.3.2 Gaucher's Disease - Market Revenue and Forecast to 2028 (US$ Million)
8.4 Fabry's Disease
8.4.1 Overview
8.4.2 Fabry's Disease - Market Revenue and Forecast to 2028 (US$ Million)
8.5 Mucopolysaccharidosis (MPS)
8.5.1 Overview
8.5.2 MPS - Market Revenue and Forecast to 2028 (US$ Million)
8.6 Pompe's Disease
8.6.1 Overview
8.6.2 Pompe's Disease - Market Revenue and Forecast to 2028 (US$ Million)
8.7 SCID
8.7.1 Overview
8.7.2 SCID - Market Revenue and Forecast to 2028 (US$ Million)
8.8 Other Therapeutic Conditions
8.8.1 Overview
8.8.2 Other Therapeutic Conditions - Market Revenue and Forecast to 2028 (US$ Million)
9. MEA Enzyme Replacement Therapy Market Analysis and Forecasts To 2028 – By Route of Administration
9.1 Overview
9.2 MEA Enzyme Replacement Therapy Market, By Route of Administration 2021 & 2028 (%)
9.3 Parenteral
9.3.1 Overview
9.3.2 Parenteral - Market Revenue and Forecast to 2028 (US$ Million)
9.4 Oral
9.4.1 Overview
9.4.2 Oral - Market Revenue and Forecast to 2028 (US$ Million)
10. MEA Enzyme Replacement Therapy Market Analysis– By End User
10.1 Overview
10.2 MEA Enzyme Replacement Therapy Market, By End User 2021 & 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals - Market Revenue and Forecasts To 2028 (US$ Million)
10.4 Infusion Centers
10.4.1 Overview
10.4.2 Infusion Centers - Market Revenue and Forecasts To 2028 (US$ Million)
10.5 Others
10.5.1 Overview
10.5.2 Others - Market Revenue and Forecasts To 2028 (US$ Million)
11. MEA Enzyme Replacement Therapy Market Revenue and Forecasts to 2028 – Country Analysis
11.1 Middle East & Africa Enzyme Replacement Therapy Market
11.1.1 Overview
11.1.2 Middle East & Africa Enzyme Replacement Therapy Market Revenue and Forecast to 2028, by Country (%)
11.1.2.1 Saudi Arabia: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (USD Million)
11.1.2.1.1 Overview
11.1.2.1.2 Saudi Arabia Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US$ Million)
11.1.2.1.3 Saudi Arabia: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Enzyme Type (US$ Million)
11.1.2.1.4 Saudi Arabia: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By Therapeutic Conditions (US$ Million)
11.1.2.1.5 Saudi Arabia: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Route of Administration (US$ Million)
11.1.2.1.6 Saudi Arabia: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By End User (US$ Million)
11.1.2.2 South Africa: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (USD Million)
11.1.2.2.1 Overview
11.1.2.2.2 South Africa Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US$ Million)
11.1.2.2.3 South Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Enzyme Type (US$ Million)
11.1.2.2.4 South Africa: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By Therapeutic Conditions (US$ Million)
11.1.2.2.5 South Africa: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By Route of Administration (US$ Million)
11.1.2.2.6 South Africa: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By End User (US$ Million)
11.1.2.3 UAE: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (USD Million)
11.1.2.3.1 Overview
11.1.2.3.2 UAE: Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US$ Million)
11.1.2.3.3 UAE: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Enzyme Type (US$ Million)
11.1.2.3.4 UAE: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By Therapeutic Conditions (US$ Million)
11.1.2.3.5 UAE: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By Route of Administration (US$ Million)
11.1.2.3.6 UAE: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By End User (US$ Million)
11.1.2.4 Rest of the Middle East and Africa: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (USD Million)
11.1.2.4.1 Overview
11.1.2.4.2 Rest of the Middle East and Africa Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US$ Million)
11.1.2.4.3 Rest of the Middle East and Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Enzyme Type (US$ Million)
11.1.2.4.4 Rest of the Middle East and Africa: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By Therapeutic Conditions (US$ Million)
11.1.2.4.5 Rest of the Middle East and Africa: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By Route of Administration (US$ Million)
11.1.2.4.6 Rest of the Middle East and Africa: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By End User (US$ Million)
12. MEA Enzyme Replacement Therapy Market–Industry Landscape
12.1 Overview
12.2 Inorganic Growth Strategies
12.2.1 Overview
12.3 Organic Growth Strategies
12.3.1 Overview
13. Company Profiles
13.1 Sanofi
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 BioMarin Pharmaceutical Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Takeda Pharmaceutical Company Limited
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 AbbVie Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.)
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Alexion Pharmaceuticals, Inc. (AstraZeneca)
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 WOT Analysis
13.6.6 Key Developments
13.7 Amicus Therapeutics
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Recordati S.p.A.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 CHIESI Farmaceutici S.p.A.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Pfizer Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Saudi Arabia: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Enzyme Type (US$ Million)
Table 2. Saudi Arabia: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Therapeutic Conditions (US$ Million)
Table 3. Saudi Arabia: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Route of Administration (US$ Million)
Table 4. Saudi Arabia: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By End User (US$ Million)
Table 5. South Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Enzyme Type (US$ Million)
Table 6. South Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Therapeutic Conditions (US$ Million)
Table 7. South Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Route of Administration (US$ Million)
Table 8. South Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By End User (US$ Million)
Table 9. UAE: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Enzyme Type (US$ Million)
Table 10. UAE: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Therapeutic Conditions (US$ Million)
Table 11. UAE: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Route of Administration (US$ Million)
Table 12. UAE: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By End User (US$ Million)
Table 13. Rest of the Middle East and Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Enzyme Type (US$ Million)
Table 14. Rest of the Middle East and Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Therapeutic Conditions (US$ Million)
Table 15. Rest of the Middle East and Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Route of Administration (US$ Million)
Table 16. Rest of the Middle East and Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By End User (US$ Million)
Table 17. Recent Inorganic Growth Strategies in the MEA enzyme replacement therapy market
Table 18. Recent Organic Growth Strategies in the MEA enzyme replacement therapy market
Table 19. Glossary of Terms
LIST OF FIGURES
Figure 1. MEA Enzyme Replacement Therapy Market Segmentation
Figure 2. MEA Enzyme Replacement Therapy Market Segmentation, By Country
Figure 3. MEA Enzyme Replacement Therapy Market Overview
Figure 4. MEA Enzyme Replacement Therapy Market, By Enzyme Type
Figure 5. MEA Enzyme Replacement Therapy Market, By Country
Figure 6. Middle East & Africa: PEST Analysis
Figure 7. Expert Opinion
Figure 8. MEA Impact Analysis
Figure 9. MEA Enzyme Replacement Therapy Market– Revenue Forecast and Analysis – 2020- 2028
Figure 10. MEA Enzyme Replacement Therapy Market, by Enzyme Type 2021 & 2028 (%)
Figure 11. MEA Alglucosidase Alfa Revenue and Forecasts to 2028 (US$ Million)
Figure 12. MEA Agalsidase Beta - Revenue and Forecasts to 2028 (US$ Million)
Figure 13. MEA Imiglucerase - Revenue and Forecasts to 2028 (US$ Million)
Figure 14. MEA Idursulfase - Revenue and Forecasts to 2028 (US$ Million)
Figure 15. MEA Galsulfase - Revenue and Forecasts to 2028 (US$ Million)
Figure 16. MEA Velaglucerase Alfa - Revenue and Forecasts to 2028 (US$ Million)
Figure 17. MEA Other Enzymes - Revenue and Forecasts to 2028 (US$ Million)
Figure 18. MEA Enzyme Replacement Therapy Market, by Therapeutic Conditions 2021 & 2028 (%)
Figure 19. MEA Gaucher's Disease - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 20. MEA Fabry's Disease - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. MEA MPS - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. MEA Pompe's Disease - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 23. MEA SCID - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 24. MEA Other Therapeutic Conditions - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. MEA Enzyme Replacement Therapy Market, by Route of Administration 2021 & 2028 (%)
Figure 26. MEA Parenteral - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 27. MEA Oral - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 28. MEA Enzyme Replacement Therapy Market, by End User 2021 & 2028 (%)
Figure 29. MEA Hospitals - Market Revenue and Forecasts To 2028 (US$ Million)
Figure 30. MEA Infusion Centers - Market Revenue and Forecasts To 2028 (US$ Million)
Figure 31. MEA Others- Market Revenue and Forecasts To 2028 (US$ Million)
Figure 32. Middle East & Africa Enzyme Replacement Therapy Market Revenue Overview, by Country, 2021 (US$ Million)
Figure 33. Middle East & Africa Enzyme Replacement Therapy Market Revenue and Forecast to 2028, by Country (%)
Figure 34. Saudi Arabia: Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US$ Million)
Figure 35. South Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US$ Million)
Figure 36. UAE: Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US$ Million)
Figure 37. Rest of the Middle East and Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US$ Million)
- Sanofi.
- BioMarine Pharmaceutical Inc.
- Takeda Pharmaceutical Company Limited.
- AbbVie Inc.
- Janssen Pharmaceutical ( Johnson & Johnson Services,Inc.).
- Alexion Pharmaceutical, Inc.(AstaZeneca).
- Amicus Therapeutics.
- Recordati S.p.A.
- CHIESI farmaceutici S.p.A.
- Pfizer Inc.